SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is trending down, sparking debate about an AI bubble. The community is actively discussing whether the drop is a market correction, profit-taking, or manipulation by institutional investors. Some also point to comments from a Fed official raising concerns about valuations as a contributing factor.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing high volatility as traders debate whether recent drops signal a larger market correction or just a temporary pullback, fueled by concerns around AI valuations and potential recession indicators. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, closely watching key support levels and VIX movements. The conversation includes speculation about the Fed's next moves and the impact of economic data on market direction.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The $QQQ is experiencing significant volatility, driven by an intense intraday sell-off despite initially gapping up on strong earnings from major tech companies. Community sentiment is shifting rapidly, with many traders expressing shock and questioning the market's fundamentals as the index reverses sharply. Discussions revolve around potential manipulation, the influence of macroeconomic factors, and whether this signals a broader market correction or just a short-term pullback.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a strong Q3 earnings report that included raised FY26 guidance and a surge in e-commerce sales, with discussion around its potential move to the Nasdaq. Community talking points include whether Walmart is a safe haven during market volatility and the impact of potential government shutdowns on SNAP benefits and consumer spending at Walmart stores.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant downturn, sparking debates about its role as a store of value and potential for further decline. Community discussions revolve around possible bottom levels, with some anticipating a substantial bounce while others fear a continued slide. The broader market context, including potential impacts from macroeconomic factors and liquidations, is also fueling uncertainty and volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as traders digest a recent price target increase from UBS, countered by potential concerns over capex spending. Community discussion revolves around the sustainability of the rally and whether the stock is currently overbought, especially in light of the broader AI-driven memory demand narrative. Some traders are pointing to potential short-term pullback scenarios.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending downwards, with community members citing general market conditions and a delayed Neutron launch as catalysts for the dip, despite a recent successful launch and positive earnings report. The community is debating whether to buy the dip or brace for further declines, with some expressing frustration while others remain bullish on the company's long-term potential and are taking the opportunity to add to their positions. Some traders attribute the drop to short sellers and broader market trends.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings ($SGBX) is trending due to a potential short squeeze, with community members highlighting the high cost to borrow, significant short interest, and limited shares available for shorting. The stock has experienced a massive volume spike and intraday volatility, fueling discussions about a potential breakout and creating a battleground between bulls and bears. Some traders are drawing comparisons to other squeeze candidates and urging each other to hold firm.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as it hits fresh 52-week lows, with the community debating whether it's a buying opportunity or if further downside is expected due to its correlation with Bitcoin. Despite the recent price drop, some traders are noting unusual call option activity, suggesting contrarian bullish bets, while others point to potential liquidation levels and debt concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.3% - What's Next?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 5.3% - Time to Sell...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Raiffeisen Bank International AG Has $723,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT

Raiffeisen Bank International AG boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 137.4% in the second quarter, according to the company in its most recent disclosure...

Bank of New York Mellon Corp Sells 641,805 Shares of Sarepta Therapeutics, Inc. $SRPT

Bank of New York Mellon Corp decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 49.7% during the second quarter, according to its most recent filing with the...

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

<ul class="summary-bullets"><li>FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.</li><li>Use of gene therapy is now limited to walking DMD patients aged four and older.</li><li>The update deepens a tough stretch for Sarepta following a failed trial and declining Elevidys revenue.</li></ul>Sarepta Therapeutics shares fell over 1% in premarket trading on Monday after the U.S. Food and Drug Administration approved new labeling for the company’s gene therapy Elevidys, adding its most serious safety warning and sharply narrowing the group of Duchenne muscular dystrophy (DMD) patients eligible to receive the drug.<h2 class="st-heading-2">FDA Tightens Restrictions Following Two Deaths</h2>The agency added a boxed warning to Elevidys after two non-ambulatory pediatric patients died from acute liver failure following treatment. The revised label removes authorization for all non-ambulatory patients, limiting use to walking patients aged four and older.In July, Sarepta had voluntarily paused distribution of the $3.2 million therapy for non-ambulatory patients after regulators issued a safety alert. The new labeling now formalizes that restriction and further shrinks the potential market for the treatment.Parent Project Muscular Dystrophy, a major advocacy group, said the update “serves as a reminder that while gene therapy breakthroughs bring promise and hope, serious questions remain about the safety and long-term outcomes of these therapies,” adding that the changes give families “a clearer understanding of who is eligible … and what monitoring is required,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-adds-strongest-warning-sarepta-gene-therapy-after-fatal-liver-injuries-2025-11-14/">report</a>.&nbsp;<h2 class="st-heading-2">Expanded Monitoring And New Post-Market Study Required</h2>Under the revised label, patients must undergo weekly liver function tests for at least three months, and remain close to an appropriate medical facility for two months after treatment.The FDA is also requiring Sarepta to run an observational study involving about 200 DMD patients, tracking liver function and safety outcomes for at least 12 months after receiving Elevidys.<h2 class="st-heading-2">Setback Caps A Difficult Year For Sarepta</h2>The label revision follows a string of setbacks for the company. Earlier this month, Sarepta said its Phase 3 ESSENCE trial for two other DMD drugs, Amondys 45 and Vyondys 53,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-crashes-after-hours-on-dmd-trial-failure-q3-print/cL2FDdvR3Ce">failed to meet its main goal</a>, showing no statistically significant benefit on stair-climb speed after 96 weeks.The company attributed part of the disappointing outcome to trial disruptions during the pandemic, stating that results looked more favorable when data affected by the pandemic was excluded.Financial pressures have also intensified. In the third quarter, revenue declined to $399.4 million from $467.2 million a year earlier, in part due to reduced Elevidys sales following June’s suspension for non-ambulatory patients. Sarepta posted a $179.9 million net loss, reversing last year’s profit, while cash reserves dropped to $865 million from $1.5 billion.<h2 class="st-heading-2">Stocktwits Bulls See Room For A Run</h2>On Stocktwits, retail sentiment for Sarepta was ‘neutral’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:962/140;" src="https://news.stocktwits-cdn.com/srpt_ss_jpg_9a8ec81686.webp" alt="srpt ss.jpg" width="962" height="140"><figcaption>SRPT sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “$25 is a reasonable target for this week. Next week we can start talking 30+.”<stembedurl>https://stocktwits.com/Roaring_Capybara/message/636403055</stembedurl>Another user said, “lets have a great week! Hopefully the biotech sector will continue to enjoy a good influx of money, acquisitions continue, and more good news for SRPT!“<stembedurl>https://stocktwits.com/Plowmaster/message/636395126</stembedurl><a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> has declined 85% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy

FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.

Equity

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Time to Buy?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8% - Here's Why...

2 Beaten-Down Stocks to Avoid Right Now

Key PointsIntellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments...

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.read more...

Sarepta Announces FDAs Approval of Updated ELEVIDYS Prescribing Information

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc